TEVA PHARMACEUTICAL INDUSTRIES LTD Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Teva Pharmaceutical Industries Ltd quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2010 to Q2 2024.
  • Teva Pharmaceutical Industries Ltd Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$846M, a 2.98% increase year-over-year.
  • Teva Pharmaceutical Industries Ltd Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$452M, a 80.6% increase year-over-year.
  • Teva Pharmaceutical Industries Ltd annual Net Income (Loss) Attributable to Parent for 2023 was -$559M, a 77.1% increase from 2022.
  • Teva Pharmaceutical Industries Ltd annual Net Income (Loss) Attributable to Parent for 2022 was -$2.45B, a 687% decline from 2021.
  • Teva Pharmaceutical Industries Ltd annual Net Income (Loss) Attributable to Parent for 2021 was $417M.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$452M -$846M +$26M +2.98% Apr 1, 2024 Jun 30, 2024 10-Q 2024-07-31
Q1 2024 -$478M -$139M +$81M +36.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 -$559M $463M +$1.76B Oct 1, 2023 Dec 31, 2023 10-K 2024-02-12
Q3 2023 -$2.32B $70M +$9M +14.8% Jul 1, 2023 Sep 30, 2023 10-K 2024-02-12
Q2 2023 -$2.33B -$872M -$621M -247% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-31
Q1 2023 -$1.71B -$220M +$735M +77% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$2.45B -$1.3B -$1.14B -718% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-12
Q3 2022 -$1.3B $61M -$231M -79.1% Jul 1, 2022 Sep 30, 2022 10-K 2024-02-12
Q2 2022 -$1.07B -$251M -$458M -221% Apr 1, 2022 Jun 30, 2022 10-K 2024-02-12
Q1 2022 -$615M -$955M -$1.03B -1340% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $417M -$159M -$309M -206% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-12
Q3 2021 $726M $292M +$4.64B Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$3.92B $207M +$67M +47.9% Apr 1, 2021 Jun 30, 2021 10-Q 2022-07-27
Q1 2021 -$3.98B $77M +$8M +11.6% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-03
Q4 2020 -$3.99B $150M +$40M +36.4% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-10
Q3 2020 -$4.03B -$4.35B -$4.04B -1285% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-27
Q2 2020 $5M $140M +$829M Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-28
Q1 2020 -$824M $69M +$174M Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-28
Q4 2019 -$998M $110M +$3B Oct 1, 2019 Dec 31, 2019 10-K 2021-02-10
Q3 2019 -$3.99B -$314M -$106M -51% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-10
Q2 2019 -$3.89B -$689M -$513M -291% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-10
Q1 2019 -$3.38B -$105M -$1.23B -109% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-10
Q4 2018 -$2.15B -$2.89B +$8.65B +75% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-21
Q3 2018 -$10.8B -$208M -$803M -135% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-21
Q2 2018 -$10B -$176M +$5.79B +97.1% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-21
Q1 2018 -$15.8B $1.12B +$475M +73.6% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-21
Q4 2017 -$16.3B -$11.5B -$10.6B -1086% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-19
Q3 2017 -$5.7B $595M +$183M +44.4% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-19
Q2 2017 -$5.89B -$5.97B -$6.22B -2450% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-19
Q1 2017 $338M $645M +$9M +1.42% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-19
Q4 2016 $329M -$973M -$1.47B -295% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-12
Q3 2016 $1.8B $412M +$309M +300% Jul 1, 2016 Sep 30, 2016 6-K 2017-11-02
Q2 2016 $1.49B $254M -$285M -52.9% Apr 1, 2016 Jun 30, 2016 6-K 2017-08-03
Q1 2016 $1.78B $636M +$190M +42.6% Jan 1, 2016 Mar 31, 2016 6-K 2017-05-11
Q4 2015 $1.59B $500M -$187M -27.2% Oct 1, 2015 Dec 31, 2015 10-K 2018-02-12
Q3 2015 $1.78B $103M -$773M -88.2% Jul 1, 2015 Sep 30, 2015 6-K 2016-11-15
Q2 2015 $2.55B $539M -$209M -27.9% Apr 1, 2015 Jun 30, 2015 6-K 2016-08-04
Q1 2015 $2.76B $446M -$298M -40.1% Jan 1, 2015 Mar 31, 2015 6-K 2016-05-09
Q4 2014 $3.06B $687M +$307M +80.8% Oct 1, 2014 Dec 31, 2014 20-F 2017-02-15
Q3 2014 $2.75B $876M +$165M +23.2% Jul 1, 2014 Sep 30, 2014 6-K 2015-10-29
Q2 2014 $2.58B $748M +$1.2B Apr 1, 2014 Jun 30, 2014 6-K 2015-07-30
Q1 2014 $1.38B $744M +$114M +18.1% Jan 1, 2014 Mar 31, 2014 6-K 2015-04-30
Q4 2013 $1.27B $380M +$60M +18.8% Oct 1, 2013 Dec 31, 2013 20-F 2016-02-11
Q3 2013 $1.21B $711M +$790M Jul 1, 2013 Sep 30, 2013 6-K 2014-10-30
Q2 2013 $419M -$452M -$1.32B -152% Apr 1, 2013 Jun 30, 2013 6-K 2014-07-31
Q1 2013 $1.73B $630M -$229M -26.7% Jan 1, 2013 Mar 31, 2013 6-K 2014-05-02
Q4 2012 $1.96B $320M -$186M -36.8% Oct 1, 2012 Dec 31, 2012 20-F 2015-02-09
Q3 2012 $2.15B -$79M -$995M -109% Jul 1, 2012 Sep 30, 2012 6-K 2013-10-31
Q2 2012 $3.14B $863M +$287M +49.8% Apr 1, 2012 Jun 30, 2012 6-K 2013-08-01
Q1 2012 $2.86B $859M +$98M +12.9% Jan 1, 2012 Mar 31, 2012 6-K 2013-05-02
Q4 2011 $2.76B $506M -$265M -34.4% Oct 1, 2011 Dec 31, 2011 20-F 2014-02-10
Q3 2011 $3.02B $916M -$134M -12.8% Jul 1, 2011 Sep 30, 2011 6-K 2012-11-01
Q2 2011 $3.16B $576M -$221M -27.7% Apr 1, 2011 Jun 30, 2011 6-K 2012-08-02
Q1 2011 $3.38B $761M +$48M +6.73% Jan 1, 2011 Mar 31, 2011 6-K 2012-05-09
Q4 2010 $3.33B $771M Oct 1, 2010 Dec 31, 2010 20-F 2013-02-12
Q3 2010 $1.05B Jul 1, 2010 Sep 30, 2010 6-K 2011-11-02
Q2 2010 $797M Apr 1, 2010 Jun 30, 2010 6-K 2011-07-28
Q1 2010 $713M Jan 1, 2010 Mar 31, 2010 6-K 2011-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.